Organism Function

UK cuts 2026 new-medicine rebate rate to 14.5% under VPAG

2 days ago talkbio0Tagged branded medicines, clawback rate, Drug Industry, drug price, Growth, Nance-Horan syndrome, rebate rate, United Kingdom, valproic acid glucuronide, Voluntary Scheme

United Kingdom; VPAG; Voluntary Scheme for Branded Medicines Pricing Access and Growth; rebate rate; clawback rate; new medicines; NHS; drug pricing; pharmaceutical industry; 2026

Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs

1 week ago talkbio0Tagged Alzheimer 's disease, Cessation of life, Child, COVID19 (disease), next-generation, Obesity, research, United States Food and Drug Administration, Vaccines, Vinay Prasad FDA memo

Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul

AstraZeneca Makes Strong Case for Baxdrostat with Detailed 24-Hour Data in Resistant Hypertension Trial

1 month ago talkbio0Tagged 24-Hour Data, aldosterone synthase inhibitor, AstraZeneca, baxdrostat, Blood Pressure, blood pressure ambulatory, Phase 3 Clinical Trials, Resistant hypertensive disorder, safety profile

AstraZeneca; baxdrostat; resistant hypertension; phase III trial; aldosterone synthase inhibitor; blood pressure; 24-hour data; ambulatory blood pressure; safety profile

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

1 month ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

1 month ago talkbio0Tagged Aging, Biotechnology, board of directors, cellular rejuvenation, David Guyer, Drug Development, epigenetic reprogramming, ER-100, Life Biosciences

Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development

More Than a Third of New Zepbound Prescriptions Driven by Lilly’s DTC Program

1 month ago talkbio0Tagged Direct-to-Consumer, discount, eli lilly, Glucagon-Like Peptide 1, Growth, LillyDirect, Market, Pricing, Sales - occupational activity, Sharing (Social Behavior), Walmart Pharmacy, Weight maintenance regimen, Zepbound

Zepbound; Eli Lilly; LillyDirect; direct-to-consumer; Walmart Pharmacy; GLP-1; weight management; discount pricing; market share; sales growth

Barinthus Biotherapeutics Announces Reverse Merger with Clywedog Therapeutics to Form New Metabolic Disease-Focused Company

2 months ago talkbio0Tagged Autoimmune Diseases, Barinthus, biotherapeutics, Board Composition, Clywedog Therapeutics, Delaware merger, lock-up, Menstruation, Metabolic Diseases, reverse merger, Scheme of Arrangement, Shareholder Ownership Structure, Topco, UK

Barinthus Biotherapeutics; Reverse Merger; Clywedog Therapeutics; Metabolic Diseases; Autoimmune Diseases; Topco; Shareholder Ownership Structure; UK Scheme of Arrangement; Delaware Merger; Self-Tender Offer; Lock-Up Period; Board Composition

Recent News: Gain Peace of Mind with the Lentiviral Experts

3 months ago talkbio0Tagged advanced manufacturing, Biological Factors, CAR-T therapy, gene therapy, Growth, immuno-oncology, lentiviral vectors, Market, regulatory approval

lentiviral vectors; CAR-T therapy; gene therapy; biologics; immuno-oncology; market growth; advanced manufacturing; regulatory approval

Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio

3 months ago talkbio0Tagged Autoimmune Diseases, clinical pipeline, Immunoregulation, Inhibitor, investors, Odyssey, Precision - temporal, preclinical programs, Protac, RIPK2, Series D financing, Technology

Odyssey Therapeutics; Series D financing; $213 million; autoimmune diseases; clinical pipeline; preclinical programs; precision immunomodulation; RIPK2 inhibitor; PROTAC technology; investors

Recent News on Scaling Up Cell & Gene Therapy Supply Chains (2025)

3 months ago talkbio0Tagged Automation, Cells, digital solutions, gene therapy, Growth, Logistics, Market, patient-specific therapies, risk mitigation, scalability, supply chain, white glove delivery

cell and gene therapy; supply chain; scalability; logistics; digital solutions; risk mitigation; white glove delivery; patient-specific therapies; automation; market growth